Home Search

viaskin - search results

If you're not happy with the results, please do another search

Viaskin Milk Patch Receives Positive Recommendation to Proceed to Phase II

0
The board overseeing the Phase I study of the milk allergy therapy found no safety concerns.
Viaskin Patch

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12.
Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial to Commence

0
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Viaskin Patch

Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut Allergy

0
According to research presented at this year's #ACAAI22 meeting.
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in DBV Technologies

0
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Neffy Intranasal Epinephrine Device

CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by Summer 2023

0
The market for epinephrine delivery may expand to include non-needle alternatives next year.
Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

2
Painless microneedle patch may provide new method for desensitization.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay...

0
The company announced they would be laying off 200 employees in Q1.
IgG Antibody

Company Developing Therapy to Prevent “Allergic Cascade” Emerges from Stealth Mode

0
IgGenix will develop a therapy that focuses on all types of food allergies and related conditions.
Paliforzia (AR101)

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

0
What it is, what it treats, who it is for, how it is used, et al.